allosteric TKIs

Oncology

pharmaphorum podcast Episode 205a - Amy Burroughs, Terns Pharmaceuticals

Doing good in people’s lives: Amy Burroughs discusses CML

Amy Burroughs, CEO, Terns Pharmaceuticals, discusses available treatments for CML, the potential of allosteric TKIs, and the wider oncology landscape.

News

GSK pursues $10.6bn takeover of cancer biotech Nuvalent

GSK is preparing for its biggest acquisition in more than 10 years, agreeing to buy cancer drug developer Nuvalent for $10.6 billion.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks